New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:13 EDTELGXEndologix announce preliminary Q4 revenue of about $29.2M, consensus $28.16M
The company anticipates U.S. Revenue to be approximately $23.3M in Q4, representing approximately 20% growth compared to $19.4M for the same quarter in 2011. International revenue is anticipated to be approximately $5.9M in Q4, representing approximately 48% growth compared to $4M for the same quarter in 2011.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:28 EDTELGXEndologix weakness a buying opportunity, says Canaccord
Canaccord would use the weakness in Endologix following its preliminary Q3 results as a chance to accumulate the shares. The firm believes the Nellix opportunity remains intact and sees its European performance as a precursor to great things to come for its technology. Canaccord reiterates its Buy rating and $17.50 price target on Endologix shares.
September 29, 2014
12:18 EDTELGXOn The Fly: Midday Wrap
Subscribe for More Information
11:39 EDTELGXEndologix plummets to 52-week low after cutting outlook
Subscribe for More Information
07:24 EDTELGXStephens to hold an investor trip
Subscribe for More Information
07:09 EDTELGXEndologix reports preliminary Q3 revenue approximately $37M, consensus $37.68M
Subscribe for More Information
07:07 EDTELGXEndologix lowers FY14 adjusted EPS view to (43c)-(37c) from (33c)-(27c)
Subscribe for More Information
06:56 EDTELGXEndologix completes enrollment in EVAS FORWARD Global Registry
Subscribe for More Information
06:51 EDTELGXEndologix to initiate prospective randomized EVAR clinical study
Endologix announced that it will conduct the first ever prospective randomized clinical study to compare outcomes in endovascular repair of abdominal aortic aneurysms. The LEOPARD Study has been designed to provide an accurate and unbiased assessment of commercially available EVAR devices with a planned enrollment of 600 patients. LEOPARD will include up to 60 active EVAR centers throughout the United States. The primary endpoint of the study is treatment success at one year based upon: procedural success; and rates of freedom from aneurysm rupture; conversion to open surgical repair; endoleaks; clinically significant device migration; aneurysm enlargement and secondary endovascular procedures. Results from the study will be independently adjudicated by a third-party. The follow-up period will be five years.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use